A novel TASK channel antagonist nasal spray reduces sleep apnea severity in physiological responders: a randomized, blinded, trial. Am J Physiol Heart Circ Physiol . 2024;326(3):H715-H723. doi:10. ...

Amneal’s Naloxone HCI Nasal Spray, manufactured in the U.S., is a generic equivalent to OTC NARCAN ® HCI Nasal Spray, a medication that is widely used to help treat drug overdose from opioids ...

Optinose (NASDAQ:OPTN), a specialty pharmaceutical company, announced today that it has received FDA approval for a new indication of its XHANCE (fluticasone propionate) nasal spray to treat ...

A clinical trial led by Weill Cornell Medicine investigators showed that a nasal spray that patients administer at home, without a physician, successfully and safely treated recurrent episodes of ...

Optinose is conservatively projecting peak sales of $300 million for its drug-device product Xhance, which had sales of about $71 million last year. A Bucks County pharmaceutical company could ...

(RTTNews) - Amneal Pharmaceuticals, Inc. (AMRX) announced on Wednesday that it has received FDA approval for its Over the Counter Naloxone Hydrochloride or HCI Nasal Spray, USP, 4mg. This nasal ...

Reference: Ip JE, Coutu B, Noseworthy PA, et al. Etripamil Nasal Spray for Recurrent Paroxysmal Supraventricular Tachycardia Conversion: Results from the NODE-303 Open-label Study. J Am Coll Cardiol.

Reference: Ip JE, Coutu B, Noseworthy PA, et al. Etripamil Nasal Spray for Recurrent Paroxysmal Supraventricular Tachycardia Conversion: Results from the NODE-303 Open-label Study. J Am Coll Cardiol.

YARDLEY, Pa., April 25, 2024 (GLOBE NEWSWIRE) -- Optinose (NASDAQ:OPTN), a pharmaceutical company focused on patients treated by ear, nose and throat (ENT) and allergy specialists, today announced ...

Editor's note: This story has been updated as of April 16, 2024 A mild winter has conspired with a warm and wet spring to create what's shaping up to be a long and intense allergy season in ...